A worldwide perspective of atypical pathogens in community-acquired pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 10, 2007, Pages 1086-1093

  Arnold, Forest W ^a   Summersgill, James T ^a   Lajoie, Andrew S ^a,b   Peyrani, Paula ^a   Marrie, Thomas J ^c   Rossi, Paolo ^d   Blasi, Francesco ^e   Fernandez, Patricia ^f   File Jr , Thomas M ^g   Rello, Jordi ^h   Menendez, Rosario ⁱ   Marzoratti, Lucia ^j   Luna, Carlos M ^k   Ramirez, Julio A ^a   Nakamatsu, Raul ^l   Myers, John ^b   Brock, Guy ^b   Bordon, Jose ^m   Gross, Peter ⁿ   Weiss, Karl ^o   Legnani, Delfino ^p   Cosentini, Roberto ^q   Bodi, Maria ^h   Torres, Antoni ^r   Porras, Jose ^s   Lode, Harmut ^t   Roig, Jorge ^u   Benchetrit, Guillermo ^v   Lopardo, Gustavo ^w   De Vedia, Lautaro ^x   Corral, Jorge ^y   Martinez, Jorge ^z   Gonzalez, Jose ^aa   Videla, Alejandro ^ab   Victorio, Carlos ^ac   Rodriguez, Eduardo ^ad   Rodriguez, Maria ^ae   Levy, Gur ^af   Arteta, Federico ^ag   Fuenzalida, Alejandro Diaz ^ah   Parada, Maria ^ai   Luna, Juan ^aj   more..

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f INSTITUTO NACIONAL DEL TÓRAX   (Chile)

^g SUMMA HEALTH SYSTEM   (United States)

^h HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j Sanatorio 9 de Julio   (Argentina)

^k HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m Providence Hospital Washington DC   (United States)

ⁿ HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^o MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^p UNIVERSITY OF MILAN   (Italy)

^q Policlinico   (Italy)

^r Instituto de Neumonologia Y Cirugia Toracica   (Spain)

^s Hospital Sant Pau i Santa Tecla   (Spain)

^t City Hospital Emil von Behring/Lungenklinik Heckeshorn   (Germany)

^u HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

^v Instituto de Investigaciones Metabolicas   (Argentina)

^w Hospital Prof Dr Bernardo Houssay   (Argentina)

^x HOSPITAL F J MUÑIZ   (Argentina)

^y Hospital Dr Oscar Alende   (Argentina)

^z Instituto Medico Platense   (Argentina)

^aa Tornu Hospital   (Argentina)

^ab UNIVERSIDAD AUSTRAL   (Argentina)

^ac Clinica Uruguay   (Argentina)

^ad HOSPITAL ESPAÑOL   (Argentina)

^ae Hospital Prof Rodolfo Rossi La Plata   (Argentina)

^af HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^ag Asociacion Cardiovascular Centroccidental Venezuela   (Venezuela)

^ah UNIVERSITY OF CHILE   (Chile)

^ai CLÍNICA LAS CONDES   (Chile)

^aj Hospital Nacional Roosevelt   (Guatemala)

more..

Author keywords

Atypical; Community acquired infection; Empiric antibiotic; Pneumonia, mycoplasma; Pneumonia, pneumococcal

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; MACROLIDE; QUINOLONE;

AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; GEOGRAPHIC DISTRIBUTION; HAZARD RATIO; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MONOTHERAPY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DATABASES, FACTUAL; HUMANS; INCIDENCE; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; WORLD HEALTH;

EID: 34248363207     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200603-350OC     Document Type: Article

References (33)

1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001;163:1730-1754.
2. Mandell LA, Marrie TJ, Grossman RE, Chow AW, Hyland RH. Canadian guidelines for the management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
3. Yanagihara K, Kohno S, Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents 2001;18:S45-S48.
4. Vogel F, Worth H, Adam D, Elies W, Ewig S, Höffken G, Lode H, Lorenz J, Scholz H, Stille W, et al. for the Paul Ehrlich Society for Chemotherapy and the German Respiratory Association. Rational treatment of bacterial respiratory tract infections. [in German] Chemotherapie Journal. 2000;1:3-23.
5. Luna CM, Ramirez J, Lopez H, Mazzei JA, Abreu de Oliveira JC, Pereira J, Jardim JR, Gonzales P, Lisboa C, Maldonado D, et al.; Grupo de trabajo de la Asociacion Latinoamericana del Torax (ALAT). Recomendaciones ALAT sobre la neumonia adquirida en la comunidad. [in Spanish] Arch Bronconeumol 2001;37:340-348.
6. Feldman C, Bateman ED, Klugman KP, Richards G, Maartens G, and Ras G, for the Working Groups of the South African Pulmonology Society and the Antibiotic Study Group of South Africa. Management of community-acquired pneumonia in adults. S Afr Med J 1996;86:1152-1163.
7. Memish Z, Shibl A, Ahmed Q. Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. Int J Antimicrob Agents 2002;20:S1-12.
8. French Infectious Diseases Society (SPILF). Guidelines of the French Infectious Diseases Society. What should the initial antibiotherapy for acute community-acquired pneumonia be?How should it be reassessed in case of failure, given the evolution of responsible pathogens and the resistance of pneumococci? Should combined treatment be used? Med Mal Infect 2001;31:357-363.
9. IMPACT working group. Reducing bacterial resistance with IMPACT - Interhospital Multi-disciplinary Programme on Antimicrobial Chemotherapy, 2nd ed. Hong Kong: Hong Kong University and Hong Kong Hospital Authority; 2001. pp. 34-35.
10. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999;160:397-405.
11. Oosterheert JJ, Bonten MJM, Hak E, Schneider MME, Hoepelman IM. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 2003;52:555-563.
12. Arnold F, Summersgill J, Blasi F, File T, Fernandez P, Porras J, Feldman C, Ramirez J. Community-acquired pneumonia due to atypical pathogens: a worldwide comparison of the incidence and initial empiric therapy. Results from the CAPO international cohort study [abstract]. Proc Am Thorac Soc 2005;2:A46.
13. Arnold F, Summergill J, Cohen MG, Ramirez J. Incidence and empiric therapy for atypical pathogens of community-acquired pneumonia: an international perspective [abstract]. Final Program and Abstracts of the Annual Meeting of the Infectious Diseases Society of America (IDSA) 2004; Boston, MA. A423.
14. Ramirez JA, Ahkee S, Tolentino A, Miller RD, Summersgill JT. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab. Diagn Microbiol Infect Dis 1996;24:7-14.
15. Fine MJ, Auble TE, Yealy DM, Hanusa DM, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Wishwa KN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
16. Zar JH. Biostatistical analysis. In: Zar JH, editor. Two-sampled hypotheses, 4th ed. Upper Saddle River, NJ: Prentice Hall; 1999. pp. 122-160.
17. Trowbridge JF, Artymowicz RJ, Lee CE, Brown PB, Farber MS, Kernan W, Beaulieu JE, Goldman MP, Yanak F, Lewis JS, et al. Antimicrobial selection and length of hospital stay in patients with community-acquired pneumonia. J Clin Outcomes Manag 2002;9:613-619.
18. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999;159:2576-2580.
19. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of non-teaching US community hospitals. Ann Pharmacother 2000;34:446-452.
20. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999;107:34S-43S.
21. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, García E, Marco MA, Torres A, Mensa J. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-395.
22. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-2572.
23. Frei CR, Koeller JM, Burgess DS, Talbert RL, Johnsrud MT. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy 2003;23:1167-1174.
24. Houck PM, MacLehose RF, Niederman MS, Lowry JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states. Chest 2001;119:1420-1426.
25. Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000;22:872-878.
26. Menéndez R, Ferrando D, Vallés JM, Martinez E, Perpiñá M. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur Respir J 2001;18:151-156.
27. Arnold F, Jain S, Christensen D, Ramirez J; CAPO Investigators. Pneumonia-related versus pneumonia-unrelated length of stay in hospitalized patients with pneumonia after switch therapy: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study [abstract]. Am J Respir Crit Care Med 2003;167:A560.
28. Barlow GD, Lamping DL, Davey PG, Nathwani D. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Lancet Infect Dis 2003;3:476-488.
29. Arnold FW, LaJoie AS, Marrie T, Rossi P, Blasi F, Luna CM, Fernandez P, Porras J, Weiss K, Feldman C, et al. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. Int J Tuberc Lung Dis. 2006;10:739-743
30. Mills GD, Oehley MR, Arrol B. Effectiveness of B-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community-acquired pneumonia: meta-analysis. BMJ 2005;330:456-462.
31. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
32. Wunderink RGA. CAP on antibiotic duration. Am J Respir Crit Care Med 2006;174:3-5.
33. Menendez R, Torres A, Zalacain R, Aspa J, Martin-Villasclaras JJ, Borderias L, Benitez-Moya JM, Ruiz-Manzano J, Rodriguez de Castro F, Blanquer J, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005;172:757-762.